Young-onset cognitive disorders (YOCD) often manifests with complex and atypical presentations due to underlying heterogenous pathologies. Therefore, a biomarker-based evaluation will allow for timely diagnosis and definitive management.
Objective:
Here, we evaluated the safety and usefulness of cerebrospinal fluid (CSF) sampling through lumbar puncture (LP) in YOCD patients in a tertiary clinical setting.
Methods:
Patients with mild cognitive impairment (MCI) and mild dementia with age of onset between 45-64 years were evaluated. Patients underwent magnetic resonance imaging and their medial temporal lobe atrophy (MTA) was rated. LP side-effects and the impact of the CSF findings on diagnosis and management were analyzed.
Results:
142 patients (53 (37.32%) MCI, 51 (35.92%) dementia of the Alzheimer’s disease [DAT] type, and 38 (26.76%) non-AD type dementia) who underwent LP between 2015 to 2021 were analyzed. Using post-LP results and MTA ratings, 74 (52.11%) patients met the AT(N) criteria for AD. 56 (39.44%) patients (28 out of 53 (50.0%) MCI, 12 out of 51 (21.43%) DAT, and 16 out of 38 (28.57%) non-AD dementia) had a change in diagnosis following LP. 13 (9.15%) patients developed side-effects post-LP (11 (84.62%) patients had headache, 1 (7.69%) patient had backache, and 1 (7.69%) patient had headache and backache). 32 (22.54%) patients had a change in management post-LP, 24 (75.0%) had medication changes, 10 (31.30%) had referrals to other specialists, and 3 (9.40%) was referred for clinical trial with disease modifying interventions.
Conclusion:
LP is well-tolerated in YOCD and can bring about relevant clinical decisions with regards to the diagnosis and management of this complex clinical condition.
HanssonO, LehmannS, OttoM, ZetterbergH, LewczukP (2019) Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s disease. Alzheimers Res Ther11, 34.
2.
Alzheimer’s Association (2021) 2021 Alzheimer’s disease facts and figures special report Race, Ethnicity and Alzheimer’s in America. Alzheimers Dement17, 327–406.
3.
LeeJC, KimSJ, HongS, KimYS (2019) Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med51, 1–10.
4.
HampelH, ShawLM, AisenP, ChenC, LleóA, IwatsuboT, IwataA, YamadaM, IkeuchiT, JiaJ, WangH, TeunissenCE, PeskindE, BlennowK, CummingsJ, VergalloA (2022) State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer’s disease. Alzheimers Dement18, 159–177.
5.
JohnsonKA, FoxNC, SperlingRA, KlunkWE (2012) Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med2, a006213.
RossorMN, FoxNC, MummeryCJ, SchottJM, WarrenJD (2010) The diagnosis of young-onset dementia. Lancet Neurol9, 793–806.
15.
MendezMF (2006) The accurate diagnosis of early-onset dementia. Int J Psychiatry Med36, 401–412.
16.
IsmailZ, SmithEE, GedaY, SultzerD, BrodatyH, SmithG, Aguera-OrtizL, SweetR, MillerD, LyketsosCG (2016) Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement12, 195–202.
17.
KandiahN, WangV, LinX, NyuMM, LimL, NgA, HameedS, WeeHL (2015) Cost related to dementia in the young and the impact of etiological subtype on cost. J Alzheimers Dis49, 277–285.
PetersenR, CaraccioloB, BrayneC, GauthierS, JelicV, FratiglioniL (2013) Mild cognitive impairment: A concept in evolution. Arch Neurol53, 1689–1699.
20.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5.
21.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
22.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
23.
SechiE, FlanaganEP (2019) Diagnosis and management of autoimmune dementia. Curr Treat Options Neurol21, 11.
Van StraatenECW, ScheltensP, KnolDL, Van BuchemMA, Van DijkEJ, HofmanPAM, KarasG, KjartanssonO, De LeeuwFE, PrinsND, SchmidtR, VisserMC, WeinsteinHC, BarkhofF (2003) Operational definitions for the NINDS-AIREN criteria for vascular dementia an interobserver study. Stroke34, 1907–1912.
27.
RascovskyK, GrossmanM (2013) Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration. Int Rev Psychiatry25, 145–158.
28.
HughesCP, BergL, DanzigerWL, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
29.
LewczukP, MatzenA, BlennowK, ParnettiL, MolinuevoJL, EusebiP, KornhuberJ, MorrisJC, FaganAM (2017) Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis55, 813–822.
30.
VandersticheleHMJ, JanelidzeS, DemeyerL, CoartE, StoopsE, HerbstV, MaurooK, BrixB, HanssonO (2016) Optimized standard operating procedures for the analysis of cerebrospinal fluid Aβ42 and the ratios of Aβ isoforms using low protein binding tubes. J Alzheimers Dis53, 1121–1132.
31.
ScheltensP, LaunerJL, BarkhofF, WeinsteinCH, vanWAG (1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. J Neurol242, 557–560.
32.
DelmotteK, SchaeverbekeJ, PoesenK, VandenbergheR (2021) Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease. Alzheimers Res Ther13, 84.
LaviR, YarnitskyD, RoweJM, WeissmanA, SegalD, AviviI (2006) Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: A randomized trial. Neurology67, 1492–1494.
38.
De WildeA, Van Der FlierWM, PelkmansW, BouwmanF, VerwerJ, GrootC, Van BuchemMM, ZwanM, OssenkoppeleR, YaqubM, KunnemanM, SmetsEMA, BarkhofF, LammertsmaAA, StephensA, Van LierE, BiesselsGJ, Van BerckelBN, ScheltensP (2018) Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: The ABIDE project. JAMA Neurol75, 1062–1070.
